After the cure: management of HCV after achievement of SVR

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Co-infection with Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) significantly worsens liver disease progression and complications compared to HCV monoinfection.
• Effective treatment of HCV leading to a sustained virologic response (SVR) can improve clinical outcomes for coinfected individuals.
• Persistent, though reduced, risks for chronic liver disease complications remain even after HCV eradication.

Purpose of the Study:

• To summarize the benefits and ongoing risks associated with achieving SVR in patients coinfected with HIV and HCV.
• To review the natural history of liver fibrosis progression in this population.
• To outline current recommendations for monitoring and managing progressive liver disease post-SVR.

Main Methods:

• Literature review focusing on outcomes following HCV treatment in coinfected patients.
• Analysis of studies examining fibrosis progression and long-term complications.
• Synthesis of clinical guidelines for patient management.

Main Results:

• SVR significantly reduces liver disease progression and complications but does not eliminate risk.
• Fibrosis can continue to progress even after viral clearance, necessitating ongoing surveillance.
• Management strategies should focus on long-term risk stratification and monitoring.

Conclusions:

• Achieving SVR is beneficial for HIV/HCV coinfected patients, improving prognosis.
• Lifelong monitoring for liver disease complications is essential post-SVR.
• Integrated care models are vital for managing the long-term health of these patients.